Loading clinical trials...

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology | Clinical Trials | Clareo Health

COMPLETED

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study

NCT02140736•Hospira, now a wholly owned subsidiary of Pfizer

View on ClinicalTrials.gov

Summary

The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.

Detailed Description

This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study with adults patients who are suffering from cancer or malignant blood disease and whose chemotherapy treatment has induced symptomatic anemia and being treated with biosimilar of epoetin to correct haemoglobin levels.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients of more than 18 years of age
•Patients presenting with anemia following chemotherapy
•Patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
•\-- The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
•Patients eligible for epoetin alfa biosimilar treatment

Exclusion Criteria

•Patients are not receiving chemotherapy
•Patients already included in an epoetin zeta trial
•Patients presenting with a contraindication to epoetin zeta
•Patients presenting with hypersensitivity to the active principle or any of the excipients
•Patient with erythroblastopenia or acquired pure red cell aplasia (APRCA)
•Patient with uncontrollable arterial hypertension
•Patients who cannot receive adequate prophylaxis by antithrombotic agents

Locations (172)

Agen, France

Aix-en-Provence, France

Ajaccio, France

Albi, France

Amboise, France

Amilly, France

Annecy, France

Antibes, France

Key Dates

Start Date

September 1, 2009

Primary Completion Date

August 1, 2011

Completion Date

August 1, 2011

Last Updated

February 28, 2024

Enrollment

2,333

ACTUAL participants

Conditions

Chemotherapy-induced Symptomatic AnemiaSolid TumorsMalignant HemopathiesLymphomasMyelomas

Interventions

Epoetin biosimilar

DRUG

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

RECRUITINGNA

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

NCT06658951

HER2-positive Advanced Malignant Solid Tumors

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

A Study of ASP1002 in Adults for Treatment of Solid Tumors

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors